title: [Candesartan Cilexetil (Atacand) induced prolonged severe cholestasis improved by extracorporeal albumin dialysis].
authors.forename: Nathalie
authors.initials: N
authors.lastname: Sturm
authors.forename: Marie-Noëlle
authors.initials: MN
authors.lastname: Hilleret
authors.forename: Thierry
authors.initials: T
authors.lastname: Dreyfus
authors.forename: Didier
authors.initials: D
authors.lastname: Barnoud
authors.forename: Vincent
authors.initials: V
authors.lastname: Leroy
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Zarski
mesh_terms: D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D001781:Blood Component Removal / Q000379:methods; D002779:Cholestasis / Q000139:chemically induced* / Q000628:therapy*; D005112:Extracorporeal Circulation; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D012709:Serum Albumin; D013777:Tetrazoles / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D012709:Serum Albumin; D013777:Tetrazoles; C077793:candesartan cilexetil